{"id":36332,"date":"2026-10-23T17:31:00","date_gmt":"2026-10-23T12:01:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=36332"},"modified":"2026-10-23T09:01:44","modified_gmt":"2026-10-23T03:31:44","slug":"vascular-dementia-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape","title":{"rendered":"Vascular Dementia Treatment Space: A Billion-Dollar Gap Waiting for Its First Approved Drug"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6adc883cbde76\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6adc883cbde76\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape\/#A_Silent_Epidemic_The_Heavy_Human_Toll_of_Vascular_Dementia\" >A Silent Epidemic: The Heavy Human Toll of Vascular Dementia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape\/#Treating_the_Vessels_Not_the_Disease_Where_Todays_Care_Falls_Short\" >Treating the Vessels, Not the Disease: Where Today&#8217;s Care Falls Short<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape\/#Beyond_Off-Label_The_Pipeline_Rewriting_the_Vascular_Dementia_Playbook\" >Beyond Off-Label: The Pipeline Rewriting the Vascular Dementia Playbook<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape\/#Resverlogixs_Apabetalone\" >Resverlogix\u2019s Apabetalone<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape\/#Charsire_Biotechnologys_BAC\" >Charsire Biotechnology\u2019s BAC<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape\/#Whats_Next_for_Vascular_Dementia_Treatment\" >What\u2019s Next for Vascular Dementia Treatment?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>Vascular dementia is the second most common form of dementia after Alzheimer\u2019s disease; however, no drug has been specifically approved for its treatment.&nbsp;<\/em><\/li>\n\n\n\n<li><em>In 2025, the total number of diagnosed prevalent cases of vascular dementia across the seven major markets was estimated at 3 million, with projections indicating an increase to 3.8 million by 2036. This upward trend highlights the growing disease burden, driven by aging populations and the increasing prevalence of cerebrovascular risk factors over the forecast period.&nbsp;<\/em><\/li>\n\n\n\n<li><em>Despite its substantial prevalence and clinical impact, pharmacological management has largely depended on the off-label use of antipsychotics, antidepressants, and sedatives, underscoring the lack of effective, durable, and disease-specific therapeutic options.<\/em><\/li>\n\n\n\n<li><em>Although the vascular dementia treatment pipeline remains relatively limited, it is gradually evolving toward more targeted, mechanism-driven approaches.&nbsp;<\/em><\/li>\n\n\n\n<li><em>Emerging candidates, including Apabetalone by Resverlogix, BAC by Charsire Biotechnology, Rifaximin SSD by Bausch Health, and PNA1 by ProNeurogen, reflect growing interest in therapeutic strategies targeting vascular modulation, epigenetic regulation, and cardiometabolic pathways that may affect cerebrovascular integrity and cognitive function.&nbsp;<\/em><\/li>\n<\/ul>\n\n\n\n<p>Vascular dementia is the second most common form of dementia after Alzheimer&#8217;s disease, yet it still has no approved drug of its own. Every pill a patient takes today was either designed for something else or aimed at the risk factors that set the disease in motion. That gap is why this indication is quietly becoming one of the most closely watched corners of neurology.<\/p>\n\n\n\n<p>The disease starts in the plumbing. When small or large blood vessels in the brain narrow, stiffen, leak or block, the brain&#8217;s wiring is starved of oxygen and nutrients. White matter degrades, the blood\u2013brain barrier weakens, and neuroinflammation builds. The result is slower thinking, poor planning, gait problems, apathy and depression, often arriving in a stepwise pattern after each vascular event. Because it overlaps so heavily with Alzheimer&#8217;s disease, it is frequently missed, or mislabeled as normal ageing, until function has already declined.<\/p>\n\n\n\n<p>The scale makes the gap hard to ignore. With ageing populations and rising rates of hypertension, diabetes and stroke, that curve is only moving one way. The pipeline is small but changing in character. Instead of borrowing Alzheimer&#8217;s therapies, a new generation of candidates targets inflammation, epigenetic regulation, the renin\u2013angiotensin system and even the gut\u2013brain axis. Here is where the vascular dementia treatment landscape stands today, and where it could go next.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-silent-epidemic-the-heavy-human-toll-of-vascular-dementia\"><span class=\"ez-toc-section\" id=\"A_Silent_Epidemic_The_Heavy_Human_Toll_of_Vascular_Dementia\"><\/span><strong>A Silent Epidemic: The Heavy Human Toll of Vascular Dementia<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Vascular dementia affects millions of families, and the numbers keep rising. In 2025, DelveInsight estimates about <strong>3 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/vascular-dementia-epidemiology-forecast\">diagnosed prevalent cases of vascular dementia<\/a> across the 7MM, split roughly as 33% in the US, 43% in EU4 and the UK, and 24% in Japan. By 2036, the 7MM total is expected to reach about <strong>3.86 million<\/strong>, growing at around 2.2% a year. Vascular dementia makes up roughly 18% of the<strong> 17.1 million <\/strong>diagnosed dementia cases across these markets today.<\/p>\n\n\n\n<p>Age is the strongest driver. In the 7MM, the <strong>81\u201390 age group<\/strong> carries the largest share, at about <strong>1.42 million<\/strong> diagnosed cases in 2025. It is followed by people aged 91 and above and those aged 71\u201380. Stroke is a major gateway. Studies cited in the report show that dementia develops in about 30% of stroke survivors, with prevalence climbing from <strong>7% <\/strong>one year after a stroke to nearly<strong> 48%<\/strong> after 25 years. Each new vascular event can bring another step down in cognition, so decline is often punctuated rather than smooth.<\/p>\n\n\n\n<p>For patients, daily life narrows quickly. Executive dysfunction makes managing money, medicines or meals difficult. Gait problems raise the risk of falls. Apathy, depression, irritability and sleep disruption wear down relationships, and some patients develop delusions or lose awareness of danger. The condition is linked to disability, higher rates of institutionalization and heavy use of healthcare services.<\/p>\n\n\n\n<p>Caregivers carry much of the load. Families often spend years managing symptoms before a diagnosis arrives, because vascular dementia is routinely mistaken for Alzheimer&#8217;s disease or normal ageing, and there is no universally accepted diagnostic biomarker. Those delays mean patients are often more impaired by the time they reach a specialist, which raises costs and caregiver strain further. At least one in ten people with dementia has mixed dementia, where vascular and Alzheimer&#8217;s pathology coexist, adding another layer of diagnostic and treatment complexity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-treating-the-vessels-not-the-disease-where-today-s-care-falls-short\"><span class=\"ez-toc-section\" id=\"Treating_the_Vessels_Not_the_Disease_Where_Todays_Care_Falls_Short\"><\/span><strong>Treating the Vessels, Not the Disease: Where Today&#8217;s Care Falls Short<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>No drug is specifically approved for vascular dementia by the US FDA, the EMA, the UK&#8217;s MHRA, or Japan&#8217;s PMDA. Care today is built on three pillars: controlling vascular risk, borrowing symptomatic <a href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market-trend\">drugs from Alzheimer&#8217;s disease<\/a>, and supportive non-drug care. The aim is to slow progression and prevent the next vascular injury, not to repair the damage already done.<\/p>\n\n\n\n<p>Risk factor control remains the foundation of vascular dementia management, with blood pressure control representing the most evidence-backed pharmacological approach to preventing the disease and slowing its progression, although no single antihypertensive class has demonstrated clear superiority. Statins are recommended for their cardiovascular benefits, while maintaining low LDL cholesterol levels, ideally below 70 mg\/dL, has been associated with slower cognitive decline. Aspirin is no longer recommended for primary prevention but may be used for secondary prevention following a stroke, alongside other antiplatelet agents such as clopidogrel and cilostazol.&nbsp;<\/p>\n\n\n\n<p>Patients with atrial fibrillation or an increased risk of cardioembolic stroke may also receive anticoagulants, including warfarin or direct oral anticoagulants. Cognitive enhancers are frequently prescribed off-label, with cholinesterase inhibitors such as donepezil, galantamine and rivastigmine widely used despite none having a specific indication for vascular dementia, and donepezil being the most commonly prescribed cognitive agent globally. However, their benefits are generally modest and often temporary, while adverse effects such as nausea, bradycardia, sleep disturbances, and weight loss may limit their use.&nbsp;<\/p>\n\n\n\n<p>Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, is also used off-label, particularly in moderate-to-severe cases or in combination with donepezil, although its benefits similarly lack long-term durability. Antipsychotics may be prescribed for severe agitation or psychosis, but their use is restricted because of the increased risk of cerebrovascular events and mortality among older adults. Similarly, anti-amyloid antibodies such as lecanemab, which are approved for Alzheimer&#8217;s disease, are not recommended for vascular dementia. Beyond pharmacological treatment, lifestyle modifications and supportive care play an important role, with regular exercise, a heart-healthy diet, social engagement and mental stimulation helping to support brain health. Cognitive rehabilitation, physical, occupational and speech therapy, along with support from nutritionists, social workers and caregivers, can help patients maintain safety and independence, while the management of falls, frailty, malnutrition and incontinence remains an essential component of care.&nbsp;<\/p>\n\n\n\n<p>Treatment practices also vary considerably across regions. In the UK, guidance from the National Institute for Health and Care Excellence (NICE) restricts the use of cholinesterase inhibitors and memantine to patients with suspected comorbid Alzheimer&#8217;s disease, <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-related-dementia-market\">Parkinson&#8217;s disease dementia<\/a> or dementia with Lewy bodies. In Germany, the plant extract Ginkgo biloba accounts for approximately 68% of anti-dementia drug use, compared with around 18% for cholinesterase inhibitors. In Japan, where anti-dementia drug use reaches 17% among individuals aged 85 years and older, donepezil remains the first-line choice for the vast majority of new users.&nbsp;<\/p>\n\n\n\n<p>Overall, the vascular dementia treatment landscape remains fragmented and heavily reliant on off-label therapies, with patients frequently switching between treatment regimens. A 2024 network meta-analysis of 194 randomized trials found that no single drug demonstrated simultaneous superiority across cognition, daily functioning, and safety, underscoring the substantial unmet medical need for therapies targeting the underlying vascular mechanisms of the disease, alongside earlier diagnosis and more standardized management approaches.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-beyond-off-label-the-pipeline-rewriting-the-vascular-dementia-playbook\"><span class=\"ez-toc-section\" id=\"Beyond_Off-Label_The_Pipeline_Rewriting_the_Vascular_Dementia_Playbook\"><\/span><strong>Beyond Off-Label: The Pipeline Rewriting the Vascular Dementia Playbook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/vascular-dementia-pipeline-insight\">vascular dementia pipeline<\/a> is thin, but it is no longer a copy of Alzheimer&#8217;s research. Candidates now aim at epigenetic regulation, neuroinflammation, the angiotensin\u2013Mas receptor pathway, and the gut\u2013brain axis. Four programs stand out, though their evidence and momentum differ sharply.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-resverlogix-s-apabetalone\"><span class=\"ez-toc-section\" id=\"Resverlogixs_Apabetalone\"><\/span><strong>Resverlogix\u2019s Apabetalone<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Apabetalone <\/strong>is a first-in-class, oral small molecule that selectively inhibits <strong>BET proteins<\/strong>, which regulate the genes behind inflammation and vascular disease. Its cognitive story comes from the BETonMACE Phase III trial (NCT02586155, 2,425 patients with type 2 diabetes and recent acute coronary syndrome), which was designed around cardiovascular events rather than dementia. Resverlogix reported significant reductions in major cardiovascular events and heart failure, and DelveInsight notes signals of cognitive benefit in pre-specified secondary analyses, including a reported 158% relative improvement in cognitive function versus placebo. The drug has FDA <strong>Breakthrough Therapy designation<\/strong> for a cardiovascular indication. No standalone vascular dementia trial is registered, so a dedicated Phase II\/III study would be needed for regulatory progress.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-charsire-biotechnology-s-bac\"><span class=\"ez-toc-section\" id=\"Charsire_Biotechnologys_BAC\"><\/span><strong>Charsire Biotechnology\u2019s BAC<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>BAC <\/strong>is a topical, plant-derived formulation built on the Taiwanese company&#8217;s patented Multi-Glycan Complex technology, with soybean extract as the raw material. It is positioned as an anti-inflammatory that aims to reduce neuroinflammation, and it is applied to the skin of the nose, scalp, and neck twice daily. The randomized, triple-masked Phase II trial (NCT02886494, 80 patients with Alzheimer&#8217;s disease or vascular dementia) was completed in 2018. DelveInsight&#8217;s review of the published data found no statistically significant gain on the primary ADAS-Cog measure and no improvement in daily living, although the treatment was well tolerated with no serious adverse events.<\/p>\n\n\n\n<p><strong>ProNeurogen\u2019s PNA1<\/strong><\/p>\n\n\n\n<p><strong>PNA1 <\/strong>is a subcutaneous peptide, a native <strong>angiotensin-(1\u20137)<\/strong> that activates the Mas receptor. The pathway is thought to calm inflammation in brain blood vessels, reduce oxidative stress, and support cerebral blood flow. ProNeurogen is developing PNA1 for vascular cognitive impairment and dementia, along with other indications, and lists a longer-acting glycosylated sibling, PNA5, in Phase I.<\/p>\n\n\n\n<p><strong>Bausch Health\u2019s Rifaximin SSD<\/strong><\/p>\n\n\n\n<p><strong>Rifaximin <\/strong>soluble solid dispersion is an oral, gut-selective antibiotic with minimal systemic exposure. The idea is to reshape gut microbiota, cut microbial inflammatory signals and ammonia and lipopolysaccharide translocation, and so protect cerebrovascular health. It is described as a non-hormonal, non-cholinergic approach. A single-blind, placebo-controlled Phase Ib\/IIa study found it safe and well tolerated, with favorable effects on systemic inflammation and dementia-related biomarkers. A dedicated Phase I\/II trial (RIDE, NCT06718686) began recruiting in December 2024. It enrolls about 20 patients, tracks stool and blood short-chain fatty acids and bile acids, and has a primary completion date of October 2027.<\/p>\n\n\n\n<p>Other programs deepen the pipeline. These include <strong>Hemostemix&#8217;s ACP-01<\/strong>, an autologous angiogenic cell therapy given intrathecally, and <strong>SciNeuro&#8217;s SNP318<\/strong>, an oral CNS-penetrant Lp-PLA2 inhibitor. Both are in Phase I.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-s-next-for-vascular-dementia-treatment\"><span class=\"ez-toc-section\" id=\"Whats_Next_for_Vascular_Dementia_Treatment\"><\/span><strong>What\u2019s Next for Vascular Dementia Treatment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/vascular-dementia-market\">vascular dementia market<\/a> across the 7MM is valued at about <strong>USD 1.3 billion<\/strong> in 2025, and DelveInsight projects it will reach <strong>USD 2 billion<\/strong> by 2036, a <strong>CAGR of 4.4%<\/strong>. That growth comes mainly from better recognition and diagnosis, a rising patient pool, and a gradually maturing pipeline, rather than from price increases on today&#8217;s low-cost generics.&nbsp;<\/p>\n\n\n\n<p>The US is the engine. It accounts for roughly two-thirds of 2025 revenue and is expected to hold that lead through 2036, helped by higher diagnostic awareness, advanced healthcare infrastructure, and greater participation in clinical research. Japan, with the oldest population, is growing more slowly in value terms because of centralized pricing, even as its patient base remains large. Today&#8217;s revenue is spread across low-cost, mostly generic products: anti-dementia drugs such as donepezil, antihypertensives, antiplatelets and anticoagulants, antidepressants, and other agents including antipsychotics.<\/p>\n\n\n\n<p>What will determine whether this future becomes a reality? Several key developments will shape the vascular dementia treatment landscape, beginning with first-mover advantage, as the first drug to receive a vascular dementia-specific label in the US, EU or UK would gain a significant edge in guideline inclusion, formulary access and reimbursement in a category that currently has no approved treatment options. Improvements in diagnosis and patient selection will also be critical, with standardized criteria, accessible imaging and validated blood-based or <a href=\"https:\/\/www.delveinsight.com\/blog\/wearables-in-digital-biomarker-development\">digital biomarkers<\/a> helping distinguish small vessel disease, large vessel disease and mixed pathology while improving the reliability of clinical trials.&nbsp;<\/p>\n\n\n\n<p>Meanwhile, mechanism-driven drug development targeting neuroinflammation, blood\u2013brain barrier integrity, angiogenesis, epigenetics and the gut\u2013brain axis offers the greatest potential for disease modification rather than symptom management alone. Given the frequent coexistence of vascular and Alzheimer&#8217;s pathology, future treatment strategies are also likely to combine risk-factor management with targeted therapies, supported by closer coordination among neurology, cardiology and primary care. Demonstrating meaningful clinical benefits beyond improvements on cognitive scales will be equally important, as payers will expect evidence of sustained improvements in daily functioning and reduced caregiver burden, alongside long-term safety data in elderly patients with substantial cardiovascular risk.&nbsp;<\/p>\n\n\n\n<p>Overall, vascular dementia represents a large, growing, and underserved market in which a substantial proportion of disease may be preventable, yet targeted treatment options remain unavailable. The next five years will be crucial in determining whether apabetalone, rifaximin SSD, PNA1 and other emerging candidates can translate promising biological mechanisms into approved therapies. Until then, effective management of blood pressure, cholesterol, and diabetes remains the most established strategy for protecting brain health.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/vascular-dementia-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Vascular-Dementia-Market-Outlook-1024x194.webp\" alt=\"Vascular Dementia Market Outlook\" class=\"wp-image-36334\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Vascular-Dementia-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Vascular-Dementia-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Vascular-Dementia-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Vascular-Dementia-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Vascular-Dementia-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/Vascular-Dementia-Market-Outlook.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary Vascular dementia is the second most common form of dementia after Alzheimer&#8217;s disease, yet it still has no approved drug of its own. Every pill a patient takes today was either designed for something else or aimed at the risk factors that set the disease in motion. That gap is why this indication is [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":36335,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[72,21809,1826,23164,23166,23168,23165,23167],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-36332","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-alzheimers-disease","tag-digital-biomarkers","tag-parkinsons-disease","tag-vascular-dementia","tag-vascular-dementia-drugs","tag-vascular-dementia-pipeline","tag-vascular-dementia-treatment","tag-vascular-dementia-trials","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>The Untapped Opportunity in Vascular Dementia Treatment<\/title>\n<meta name=\"description\" content=\"Vascular dementia treatment market across 7MM is valued at $1.3Bn in 2025, and DelveInsight projects it will reach $2Bn by 2036.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Untapped Opportunity in Vascular Dementia Treatment\" \/>\n<meta property=\"og:description\" content=\"Vascular dementia treatment market across 7MM is valued at $1.3Bn in 2025, and DelveInsight projects it will reach $2Bn by 2036.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-23T12:01:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/vascular-dementia-treatment-landscape.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Untapped Opportunity in Vascular Dementia Treatment","description":"Vascular dementia treatment market across 7MM is valued at $1.3Bn in 2025, and DelveInsight projects it will reach $2Bn by 2036.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"The Untapped Opportunity in Vascular Dementia Treatment","og_description":"Vascular dementia treatment market across 7MM is valued at $1.3Bn in 2025, and DelveInsight projects it will reach $2Bn by 2036.","og_url":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-10-23T12:01:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/vascular-dementia-treatment-landscape.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"Vascular Dementia Treatment Space: A Billion-Dollar Gap Waiting for Its First Approved Drug","datePublished":"2026-10-23T12:01:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape"},"wordCount":2143,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/vascular-dementia-treatment-landscape.webp","keywords":["Alzheimer\u2019s disease","Digital Biomarkers","Parkinson\u2019s disease","Vascular Dementia","Vascular Dementia Drugs","Vascular Dementia Pipeline","Vascular Dementia Treatment","Vascular Dementia Trials"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape","name":"The Untapped Opportunity in Vascular Dementia Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/vascular-dementia-treatment-landscape.webp","datePublished":"2026-10-23T12:01:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Vascular dementia treatment market across 7MM is valued at $1.3Bn in 2025, and DelveInsight projects it will reach $2Bn by 2036.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/vascular-dementia-treatment-landscape#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/vascular-dementia-treatment-landscape.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/vascular-dementia-treatment-landscape.webp","width":466,"height":284,"caption":"vascular-dementia-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/10\/vascular-dementia-treatment-landscape-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Digital Biomarkers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vascular Dementia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vascular Dementia Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vascular Dementia Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vascular Dementia Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Vascular Dementia Trials<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Digital Biomarkers<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Vascular Dementia<\/span>","<span class=\"advgb-post-tax-term\">Vascular Dementia Drugs<\/span>","<span class=\"advgb-post-tax-term\">Vascular Dementia Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Vascular Dementia Treatment<\/span>","<span class=\"advgb-post-tax-term\">Vascular Dementia Trials<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 17 hours ago","modified":"Updated 1 day ago"},"absolute_dates":{"created":"Posted on Oct 23, 2026","modified":"Updated on Oct 23, 2026"},"absolute_dates_time":{"created":"Posted on Oct 23, 2026 5:31 pm","modified":"Updated on Oct 23, 2026 9:01 am"},"featured_img_caption":"vascular-dementia-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=36332"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36332\/revisions"}],"predecessor-version":[{"id":36337,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36332\/revisions\/36337"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/36335"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=36332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=36332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=36332"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=36332"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=36332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}